BAMCO INC /NY/ - REVANCE THERAPEUTICS INC ownership

REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 195 filers reported holding REVANCE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.35 and the average weighting 0.2%.

Quarter-by-quarter ownership
BAMCO INC /NY/ ownership history of REVANCE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$11,702,084
-58.8%
1,020,234
-9.1%
0.03%
-57.0%
Q2 2023$28,414,676
-17.5%
1,122,666
+5.0%
0.08%
-23.3%
Q1 2023$34,448,047
+48.4%
1,069,483
-15.0%
0.10%
+32.1%
Q4 2022$23,217,290
-50.0%
1,257,708
-26.9%
0.08%
-48.0%
Q3 2022$46,454,000
+99.7%
1,720,508
+2.2%
0.15%
+100.0%
Q2 2022$23,259,000
-14.3%
1,683,008
+20.9%
0.08%
+11.9%
Q1 2022$27,152,000
+19.5%
1,392,4080.0%0.07%
+39.6%
Q4 2021$22,724,000
-41.4%
1,392,4080.0%0.05%
-45.5%
Q3 2021$38,792,000
+15.4%
1,392,408
+22.8%
0.09%
+14.3%
Q2 2021$33,610,000
+10.1%
1,133,932
+3.9%
0.08%
+2.7%
Q1 2021$30,514,000
+45.2%
1,091,732
+47.2%
0.08%
+44.2%
Q4 2020$21,021,000
+43.7%
741,732
+27.5%
0.05%
+15.6%
Q3 2020$14,625,000
+2.9%
581,7320.0%0.04%
-11.8%
Q2 2020$14,206,000
+89.4%
581,732
+14.8%
0.05%
+37.8%
Q1 2020$7,500,000
-44.2%
506,732
-38.8%
0.04%
-27.5%
Q4 2019$13,434,000
+24.8%
827,7320.0%0.05%
+15.9%
Q3 2019$10,761,000
+30.6%
827,732
+30.3%
0.04%
+33.3%
Q2 2019$8,239,000
+2.7%
635,200
+24.7%
0.03%
-2.9%
Q1 2019$8,025,000
+1190.2%
509,200
+1597.3%
0.03%
+1600.0%
Q1 2015$622,000
-14.6%
30,000
-30.2%
0.00%
-33.3%
Q4 2014$728,000
-12.4%
43,0000.0%0.00%0.0%
Q3 2014$831,000
+22.2%
43,000
+115.0%
0.00%0.0%
Q2 2014$680,000
+23.4%
20,000
+14.3%
0.00%
+50.0%
Q1 2014$551,00017,5000.00%
Other shareholders
REVANCE THERAPEUTICS INC shareholders Q4 2022
NameSharesValueWeighting ↓
Essex Woodlands Management, Inc. 3,342,047$94,714,00024.58%
Palo Alto Investors LP 2,673,313$75,762,0003.97%
Evolutionary Tree Capital Management, LLC 89,348$2,532,0001.93%
RICE HALL JAMES & ASSOCIATES, LLC 1,121,152$31,773,0001.12%
ArrowMark Colorado Holdings LLC 2,964,135$84,004,0000.65%
Rhenman & Partners Asset Management AB 220,000$6,235,0000.51%
Fosun International Ltd 233,841$6,627,0000.43%
OSTERWEIS CAPITAL MANAGEMENT INC 174,970$4,959,0000.30%
ESSEX INVESTMENT MANAGEMENT CO LLC 76,671$2,173,0000.27%
Tekla Capital Management LLC 213,808$6,059,0000.21%
View complete list of REVANCE THERAPEUTICS INC shareholders